Literature DB >> 2140598

P210 BCR-ABL is complexed to P160 BCR and ph-P53 proteins in K562 cells.

M L Campbell1, W Li, R B Arlinghaus.   

Abstract

The BCR gene (Groffen et al., 1984) plays a critical role in the pathogenesis of human leukemias that involve the Philadelphia chromosome (Ph1) (Rowley, 1973; Nowell & Hungerford, 1960). Cells containing the Ph1 contain a chimeric gene formed from the fusion of BCR (Collins et al., 1987; Lifshitz et al. 1988) and ABL genes that results from the reciprocal translocation of segments of chromosomes 9 and 22 (Shtivelman et al., 1985). The product of this chimera is a 210 kDa protein, termed P210 BCR-ABL, that possesses an activated tyrosine kinase activity (Konopka et al., 1984; Kloetzer et al., 1985). Studies using long-term marrow culture systems and retrovirus-mediated gene transfer have documented that P210 BCR-ABL can stimulate the growth of immature hematopoietic precursor cell types (McLaughlin et al., 1987; Young & Witte, 1984). We have previously reported that P210 BCR-ABL exists in cytoplasmic complexes in association with a 53 kDa protein termed ph-P53 (Maxwell et al., 1987; Li et al. 1988). Similarly, BCR proteins have been found in cytoplasmic complexes containing ph-P53 in cells lacking the Ph1 (Li et al., 1989). These BCR protein complexes possess an associated ser/thr protein kinase activity. In this same study, we found that P210-containing complexes phosphorylate BCR proteins on tyrosine residues in vitro (Li et al., 1989). We now present results which demonstrate that P210 BCR-ABL is tightly associated with P160 BCR and ph-P53 proteins in cytoplasmic complexes from cells containing the Ph1.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2140598

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  Inhibition of Bcr serine kinase by tyrosine phosphorylation.

Authors:  J Liu; Y Wu; G Z Ma; D Lu; L Haataja; N Heisterkamp; J Groffen; R B Arlinghaus
Journal:  Mol Cell Biol       Date:  1996-03       Impact factor: 4.272

2.  Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide.

Authors:  T Skorski; M Nieborowska-Skorska; N C Nicolaides; C Szczylik; P Iversen; R V Iozzo; G Zon; B Calabretta
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

3.  A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins.

Authors:  J R McWhirter; D L Galasso; J Y Wang
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

4.  Hormone-conditional transformation by fusion proteins of c-Abl and its transforming variants.

Authors:  P Jackson; D Baltimore; D Picard
Journal:  EMBO J       Date:  1993-07       Impact factor: 11.598

5.  Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway.

Authors:  L Puil; J Liu; G Gish; G Mbamalu; D Bowtell; P G Pelicci; R Arlinghaus; T Pawson
Journal:  EMBO J       Date:  1994-02-15       Impact factor: 11.598

6.  The COOH terminus of the c-Abl tyrosine kinase contains distinct F- and G-actin binding domains with bundling activity.

Authors:  R A Van Etten; P K Jackson; D Baltimore; M C Sanders; P T Matsudaira; P A Janmey
Journal:  J Cell Biol       Date:  1994-02       Impact factor: 10.539

7.  Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth.

Authors:  T Skorski; P Kanakaraj; D H Ku; M Nieborowska-Skorska; E Canaani; G Zon; B Perussia; B Calabretta
Journal:  J Exp Med       Date:  1994-06-01       Impact factor: 14.307

8.  p120 GAP requirement in normal and malignant human hematopoiesis.

Authors:  T Skorski; P Kanakaraj; M Nieborowska-Skorska; M Ratajczak; C Szczylik; G Zon; R B Arlinghaus; A Gewirtz; B Perussia; B Calabretta
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

9.  Differences in structural elements of Bcr-Abl oncoprotein isoforms in Chronic Myelogenous Leukemia.

Authors:  Abdul Hai; Nadeem A Kizilbash; Syeda Huma H Zaidi; Jamal Alruwaili; Khuram Shahzad
Journal:  Bioinformation       Date:  2014-03-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.